Fluciclovine PET/CT locates recurrent prostate cancer and advises management

(Society of Nuclear Medicine and Molecular Imaging) The addition of fluorine-18 (18F)-fluciclovine positron emission tomography/computed tomography (PET/CT) to the diagnostic work-up of patients with biochemical recurrence of prostate cancer locates previously undetected lesions and changes treatment management for the majority of patients, according to a clinical trial report presented at the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

Comments
%d bloggers like this: